Carl Zeiss Meditec AG (XSWX:AFX) Institutional Ownership: 14.66% (As of Jul. 03, 2026)


XSWX:AFX Carl Zeiss Meditec AG XSWX:AFX
67 GF Score
Price CHF25.22
GF Value CHF65.97
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Carl Zeiss Meditec AG Institutional Ownership?

Carl Zeiss Meditec AG XSWX:AFX +0.48% 67 Institutional Ownership is 14.66% as of Jul. 03, 2026. GuruFocus rates XSWX:AFX with a GF Score™ of 67/100 and a GF Value™ of CHF65.97 (Significantly Undervalued). The stock has 4 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Carl Zeiss Meditec AG's institutional ownership is 14.66%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Carl Zeiss Meditec AG's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Carl Zeiss Meditec AG's Float Percentage Of Total Shares Outstanding is 0.00%.

Carl Zeiss Meditec AG Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Carl Zeiss Meditec AG's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Carl Zeiss Meditec AG Institutional Ownership Chart

Carl Zeiss Meditec AG Historical Data

The historical data trend for Carl Zeiss Meditec AG can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 21.06 20.65 20.49 20.95 19.90 19.58 14.24 14.37 14.63 14.66
XSWX:AFX
67GF Score
Carl Zeiss Meditec AG XSWX:AFX
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Carl Zeiss Meditec AG Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 14.66% mean?
Carl Zeiss Meditec AG (XSWX:AFX) has a Institutional Ownership of 14.66% as of Jul. 03, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Carl Zeiss Meditec AG and its competitors.
Is Carl Zeiss Meditec AG's Institutional Ownership too high?
Carl Zeiss Meditec AG's current Institutional Ownership is 14.66%. Overall, Carl Zeiss Meditec AG has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Carl Zeiss Meditec AG's Institutional Ownership compare to ISRG and BDX?
Carl Zeiss Meditec AG's Institutional Ownership of 14.66% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Medical Devices & Instruments company?
A good Institutional Ownership depends on the Medical Devices & Instruments industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Carl Zeiss Meditec AG and its competitors. Carl Zeiss Meditec AG's current Institutional Ownership is 14.66%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carl Zeiss Meditec AG stock overvalued right now?
Based on GuruFocus' analysis, Carl Zeiss Meditec AG (XSWX:AFX) is currently considered Significantly Undervalued. The stock's GF Value™ is CHF65.97, compared to a current price of CHF25.22 — trading 61.8% below its estimated fair value. The current Institutional Ownership is 14.66%. Carl Zeiss Meditec AG's overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Carl Zeiss Meditec AG (XSWX:AFX), the current Institutional Ownership is 14.66% as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Carl Zeiss Meditec AG (XSWX:AFX) Overvalued in 2026?

Based on GuruFocus' analysis, Carl Zeiss Meditec AG stock appears to be undervalued. The current stock price of CHF25.22 is trading 61.8% below its estimated GF Value™ of CHF65.97. GuruFocus considers Carl Zeiss Meditec AG to be Significantly Undervalued.

Key valuation signals for XSWX:AFX:

  • Institutional Ownership: 14.66%
  • GF Value™: CHF65.97 vs. price of CHF25.22 (61.8% below fair value)
  • GF Score™: 67/100 with 4 warning signs

No single metric tells the full story. See the XSWX:AFX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Carl Zeiss Meditec AG Business Description

Address Goschwitzer Strasse 51-52, Jena, TH, DEU, 07745
Carl Zeiss Meditec is one of the largest visioncare technology companies in the world, and it operates in two segments: ophthalmic devices and microsurgery. OPT, which made up about 75% of sales in 2025, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.
67GF Score

Get the complete analysis for XSWX:AFX

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF25.22
Price
CHF65.97
GF Value